SPET in psychopharmacolgy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 49, Issue 2, 2005, Pages 205-214

  Moresco, R M ^a   Fazio, F ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Molecular imaging; Psychiatry; Radiopharmaceuticals; Tomography, emission computed, single photon

Indexed keywords

PSYCHOTROPIC AGENT;

ANIMAL; BRAIN; CLINICAL PRACTICE; DRUG EFFECT; HUMAN; MENTAL DISEASE; METHODOLOGY; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BRAIN; HUMANS; MENTAL DISORDERS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 33749335689     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Laruelle M, Wallace E, Seibyl JP, Baldwin RM, Zea-Ponce Y, Zoghbi SS et al. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-94.
2. Laruelle M, Abi-Dargham A, al-Tikriti MS, Baldwin RM, Zea-Ponce Y, Zoghbi SS et al. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 1994;14:453-65.
3. Laruelle M, Baldwin RM, Rattner Z, al-Tikriti MS, Zea-Ponce Y, Zoghbi SS et al. SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: I. Kinetic modeling of single bolus experiments. J Cereb Blood Flow Metab 1994;14:439-52.
4. Pinborg LH, Videbaek C, Knudsen GM, Swahn CG, Halldin C, Friberg L et al. Dopamine D(2) receptor quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse 2000;36:322-9.
5. Millet P, Graf C, Buck A, Walder B, Westera G, Broggini C et al. Similarity and robustness of PET and SPECT binding parameters for benzodiazepine receptors. J Cereb Blood Flow Metab 2000;20:1587-603.
6. Heinz A, Jones DW, Raedler T, Coppola R, Knable MB, Weinberger DR. Neuropharmacological studies with SPECT in neuropsychiatric disorders. Nucl Med Biol 2000;27:677-82.
7. Eckelman WC. Sensitivity of new radiopharmaceuticals. Nucl Med Biol 1998;25:169-73.
8. Kung HF, Kung MP, Choi SR. Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med 2003;33:2-13.
9. Eckelman WC. Receptors labeled with gamma-emitting radiotracers. Int J Rad Appl Instrum B 1986;13:135-9.
10. Bourguignon MH, Pauwels EK, Loc'h C, Maziere B. Iodine-123 labeled radiopharmaceuticals and single-photon emission tomography: a natural liaison. Eur J Nucl Med 1997;24:331-44.
11. Maziere B, Loc'h C. Use of bromine-76 and iodine-123 radiohalogenated tracers in the drug development process. Curr Pharm Des 2001;7:1931-43.
12. Kuikka JT, Akerman K, Bergstrom KA, Karhu J, Hiltunen J, Haukka J et al. Iodine-123 labeled N-(2-fluoroethyl)-2 beta-carbomethoxy-3 beta-(4-iodophenyl) nortropane for dopamine transporter imaging in the living human brain. Eur J Nucl Med 1995;22:682-6.
13. Pinborg LH, Videbaek C, Svarer C, Yndgaard S, Paulson OB, Knudsen GM. Quantification of [(123)I]PE2I binding to dopamine transporters with SPET. Eur J Nucl Med Mol Imaging 2002;29:623-31.
14. Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sea 1993;94:137-46.
15. Abi-Dargham A, Gandelman MS, DeErausquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996;37:1129-33.
16. Billings J, Kung MP, Chumpradit S, Pan S, Kung HF. [125I](+/-)FISCH: a new CNS D-1 dopamine receptor imaging ligand. Life Sci 1989;45:711-8.
17. Billings JJ, Guo YZ, Kung MP, Kung HF. Localization of IBF as a D-2 dopamine receptor imaging agent in nonhuman primates. Eur J Nucl Med 1993;20:1146-53.
18. Chabriat H, Levasseur M, Vidailhet M, Loc'h C, Maziere B, Bourguignon MH et al. In-vivo SPECT imaging of D2 receptor with iodine-iodolisuride: results in supranuclear palsy. J Nucl Med 1992;33:1481-5.
19. Kung HF, Guo YZ, Billings J, Xu X, Mach RH, Blau M et al. Preparation and biodistribution of [125I]IBZM: a potential CNS D2 dopamine receptor imaging agent. Int J Rad Appl Instrum B 1988;15:195-201. (Pubitemid 18035185)
20. Kessler RM, Votaw JR, Schmidt DE, Ansari MS, Holdeman KP, de Paulis T et al. High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. Life Sci 1993;53:241-50.
21. Hogberg T, Strom P, Hall H, Kohler C, Halldin C, Farde L. Syntheses of [123I]-, [125I]- and unlabelled (S)-3-iodo-5,6-dimethoxy-N-[(1-ethyl-2- pyrrolidinyl)methyl]salicylamide (NCQ 298), selective ligands for the study of dopamine D-2 receptors. Acta Pharm Nord 1990;2:53-60.
22. Ryding E, Tuninger E, Ohlsson T, Sjoholm H, Freccero-Rosman K, Levander S et al. Dopamine D2-receptor density in humans as assessed with SPET and the new high-affinity ligand 123I-NCQ298: a pilot study. Nucl Med Commun 1998;19:263-70.
23. Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW et al. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 2000;47:96-106.
24. Fujita M, Verhoeff NP, Varrone A, Zoghbi SS, Baldwin RM, Jatlow PA et al. Imaging extrastriatal dopamine D(2) receptor occupancy by endogenous dopamine in healthy humans. Eur J Pharmacol 2000;387:179-88.
25. Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M et al. Selective in vitro and in vivo binding of [(125)I]ADAM to serotonin transporters in rat brain. Synapse 2000;38:403-12.
26. Jagust WJ, Eberling JL, Biegon A, Taylor SE, VanBrocklin HF, Jordan S et al. Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. J Nucl Med 1996;37:1207-14.
27. Goodman MM, Chen P, Plisson C, Martarello L, Galt J, Votaw JR et al. Synthesis and characterization of iodine-123 labeled 2beta-carbomethoxy-3beta- (4′-((Z)-2-iodoethenyl)phenyl)nortropane. A ligand for in vivo imaging of serotonin transporters by single-photon-emission tomography. J Med Chem 2003;46:925-35.
28. Chalon S, Bronquard C, Vercouillie J, Kodas E, Garreau L, Bodard S et al. ADAM is an effective tool for in vivo study of serotonergic function: validation in rat models. Synapse 2004;52:136-42.
29. Peremans K, Audenaert K, Jacobs F, Dumont F, De Vos F, Van De Wiele C et al. Biodistribution and displacement studies of the selective 5-HT2A receptor antagonist 123I-5-I-R91150 in the normal dog. Nucl Med Commun 2002;23:1019-27. (Pubitemid 35178304)
30. Holl K, Deisenhammer E, Dauth J, Carmann H, Schubiger PA. Imaging benzodiazepine receptors in the human brain by single photon emission computed tomography (SPECT). Int J Rad Appl Instrum B 1989;16:759-63.
31. Johnson EW, Woods SW, Zoghbi S, McBride BJ, Baldwin RM, Innis RB. Receptor binding characterization of the benzodiazepine radioligand 125I-Ro16-0154: potential probe for SPECT brain imaging. Life Sci 1990;47:1535-46.
32. Schubiger PA, Hasler PH, Beer-Wohlfahrt H, Bekier A, Oettli R, Cordes M et al. Evaluation of a multicentre study with Iomazenil: a benzodiazepine receptor ligand. Nucl Med Commun 1991;12:569-82.
33. Katsifis A, Mardon K, Mattner F, Loc'h C, McPhee ME, Dikic B et al. Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. Nucl Med Biol 2003;30:191-8.
34. Kuhl DE, Koeppe RA, Fessler JA, Minoshima S, Ackermann RJ, Carey JE et al. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 1994;35:405-10.
35. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40:399-410.
36. Lee KS, He XS, Jones DW, Coppola R, Gorey JG, Knable MB et al. An improved method for rapid and efficient radioiodination of iodine-123-IQNB. J Nucl Med 1996;37:2021-4.
37. Muller-Gartner HW, Wilson AA, Dannals RF, Wagner HN Jr, Frost JJ. Imaging muscarinic cholinergic receptors in human brain in vivo with Spect, [123I]4-iododexetimide, and [123I]4-iodolevetimide. J Cereb Blood Flow Metab 1992;12:562-70.
38. Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology (Berl) 2001;156:53-7.
39. Fujita M, Seibyl JP, Vaupel DB, Tamagnan G, Early M, Zoghbi SS et al. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123i]5-i-A-85380 in healthy human subjects. Eur J Nucl Med Mol Imaging 2002;29:183-90.
40. Fujita M, Al-Tikriti MS, Tamagnan G, Zoghbi SS, Bozkurt A, Baldwin RM et al. Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380. Synapse 2003;48:116-22.
41. Bressan RA, Pilowsky LS. Imaging the glutamatergic system in vivo: relevance to schizophrenia. Eur J Nucl Med 2000;27:1723-31.
42. Waterhouse RN. Imaging the PCP site of the NMDA ion channel. Nucl Med Biol 2003;30:869-78.
43. Erlandsson K, Bressan RA, Mulligan RS, Gunn RN, Cunningham VJ, Owens J et al. Kinetic modelling of [123I]CNS 1261: a potential SPET tracer for the NMDA receptor. Nucl Med Biol 2003;30:441-54.
44. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE et al. In-vivo measurement of activated microglia in dementia. Lancet 2001;358:461-7.
45. Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW et al. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001;124(Pt 10):2014-27.
46. Pappata S, Levasseur M, Gunn RN, Myers R, Crouzel C, Syrota A et al. Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195. Neurology 2000;55:1052-4.
47. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000;123( Pt 11):2321-37.
48. Gildersleeve DL, Van Dort ME, Johnson JW, Sherman PS, Wieland DM. Synthesis and evaluation of [123I]-iodo-PK11195 for mapping peripheral-type benzodiazepine receptors (omega 3) in heart. Nucl Med Biol 1996;23:23-8.
49. Versijpt J, Dumont F, Thierens H, Jansen H, De Vos F, Slegers G et al. Biodistribution and dosimetry of [123I]iodo-PK 11195: a potential agent for SPET imaging of the peripheral benzodiazepine receptor. Eur J Nucl Med 2000;27:1326-33.
50. Versijpt JJ, Dumont F, Van Laere KJ, Decoo D, Santens P, Audenaert K et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur Neurol 2003;50:39-47.
51. Johannsen B, Pietzsch HJ. Development of technetium-99m-based CNS receptor ligands: have there been any advances? Eur J Nucl Med Mol Imaging 2002;29:263-75.
52. Eckelman WC. Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems. Eur J Nucl Med 1995;22:249-63.
53. Meegalla S, Plossl K, Kung MP, Chumpradit S, Stevenson DA, Frederick D et al. Tc-99m-Tabeled tropanes as dopamine transporter imaging agents. Bioconjug Chem 1996;7:421-9. (Pubitemid 26312132)
54. Kung MP, Stevenson DA, Plossl K, Meegalla SK, Beckwith A, Essman WD et al. [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997;24:372-80. (Pubitemid 27183040)
55. Meltzer PC, Blundell P, Zona T, Yang L, Huang H, Bonab AA et al. A second-generation 99m technetium single photon emission computed tomography agent that provides in vivo images of the dopamine transporter in primate brain. J Med Chem 2003;46:3483-96.
56. Pietzsch HJ, Scheunemann M, Kretzschmar M, Elz S, Pertz HH, Seifert S et al. Synthesis and autoradiographic evaluation of a novel high-affinity Tc-99m ligand for the 5-HT2A receptor. Nucl Med Biol 1999;26:865-75.
57. Heimbold I, Drews A, Syhre R, Kretzschmar M, Pietzsch HJ, Johannsen B. A novel technetium-99m radioligand for the 5-HT(1A) receptor derived from desmethyl-WAY-100635 (DWAY). Eur J Nucl Med Mol Imaging 2002;29:82-7.
58. Heimbold I, Drews A, Kretzschmar M, Varnas K, Hall H, Halldin C et al. Synthesis, biological and autoradiographic evaluation of a novel Tc-99m radioligand derived from WAY 100635 with high affinity for the 5-HT(1A) receptor and the alpha1-adrenergic receptor. Nucl Med Biol 2002;29:375-87.
59. Herschman HR. Molecular imaging: looking at problems, seeing solutions. Science 2003;302:605-8.
60. Meng LJ, Clinthorne NH. A modified uniform Cramer-Rao bound for multiple pinhole aperture design. IEEE Trans Med Imaging 2004;23:896-902.
61. Zheng GL, Gagnon D. CdZnTe strip detector SPECT imaging with a slit collimator. Phys Med Biol 2004;49:2257-71.
62. Green MV, Seidel J, Vaquero JJ, Jagoda E, Lee I, Eckelman WC. High resolution PET, SPECT and projection imaging in small animals. Comput Med Imaging Graph 2001;25:79-86.
63. Del Guerra A, Belcari N. Advances in animal PET scanners. Q J Nucl Med 2002;46:35-47.
64. Acton PD, Kung HF. Small animal imaging with high resolution single photon emission tomography. Nucl Med Biol 2003;30:889-95.
65. Shah K, Jacobs A, Breakefield XO, Weissleder R. Molecular imaging of gene therapy for cancer. Gene Ther 2004;11:1175-87.
66. de Win MM, de Jeu RA, de Bruin K, Habraken JB, Reneman L, Booij J et al. Validity of in vivo [123I]beta-CIT SPECT in detecting MDMA-induced neurotoxicity in rats. Eur Neuropsychopharmacol 2004;14:185-9.
67. de Win MM, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W. Mood disorders and serotonin transporter density in ecstasy users: the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl) 2004;173:376-82.
68. Acton PD, Hou C, Kung MP, Plossl K, Keeney CL, Kung HF. Occupancy of dopamine D2 receptors in the mouse brain measured using ultra-high-resolution single-photon emission tomography and [123]IBF. Eur J Nucl Med Mol Imaging 2002;29:1507-15.
69. Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002;29:1623-9.
70. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-23. (Pubitemid 37336924)
71. Leenders KL. Significance of non-presynaptic SPECT tracer methods in Parkinson's disease. Mov Disord 2003;18 Suppl 7:S39-42.
72. Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun 2001;22:819-27. (Pubitemid 32613445)
73. Zakzanis KK, Hansen KT. Dopamine D2 densities and the schizophrenic brain. Schizophr Res 1998;32:201-6.
74. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998;42:211-21. (Pubitemid 28529874)
75. Perez V, Catafau AM, Corripio I, Martin JC, Alvarez E. Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:767-70.
76. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003;160:118-27.
77. Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D'Souza DC, Krystal J et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT. Biol Psychiatry 2000;47:371-9.
78. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44:1090-8.
79. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003;28:413-20.
80. Hesse S, Barthel H, Hermann W, Murai T, Kluge R, Wagner A et al. Regional serotonin transporter availability and depression are correlated in Wilson's disease. J Neural Transm 2003;110:923-33.
81. van Dyck CH, Malison RT, Staley JK, Jacobsen LK, Seibyl JP, Laruelle M et al. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004;161:525-31.
82. van Heeringen C, Audenaert K, Van Laere K, Dumont F, Slegers G, Mertens J et al. Prefrontal 5-HT2a receptor binding index, hopelessness and personality characteristics in attempted suicide. J Affect Disord 2003;74:149-58.
83. Moresco FM, Dieci M, Vita A, Messa C, Gobbo C, Galli L et al. In vivo serotonin 5HT(2A) receptor binding and personality traits in healthy subjects: a positron emission tomography study. Neuroimage 2002;17:1470-8.
84. Audenaert K, Van Laere K, Dumont F, Vervaet M, Goethals I, Slegers G et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med 2003;44:163-9.
85. Chang L, Cloak CC, Ernst T. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. J Clin Psychiatry 2003;64 Suppl 3:7-14.
86. Kugaya A, Sanacora G, Verhoeff NP, Fujita M, Mason GF, Seneca NM et al. Cerebral benzodiazepine receptors in depressed patients measured with [123I]iomazenil SPECT. Biol Psychiatry 2003;54:792-9.
87. Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C et al. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 1999;141:175-81.
88. Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 2001;158:926-30.
89. Meisenzahl EM, Dresel S, Frodl T, Schmitt GJ, Preuss UW, Rossmuller B et al. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J Psychopharmacol 2000;14:364-70.
90. Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2000;150:132-40.
91. Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 2003;23:5-14.
92. Barnas C, Quiner S, Tauscher J, Hilger E, Willeit M, Kufferle B et al. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology (Berl) 2001;157:236-42.
93. Stephenson CM, Bigliani V, Jones HM, Mulligan RS, Acton PD, Visvikis D et al. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. [(123)I]-epidepride single photon emission tomography(SPET) study. Br J Psychiatry 2000;177:408-15.
94. Bigliani V, Mulligan RS, Acton PD, Visvikis D, Ell PJ, Stephenson C et al. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine 87. receptors by typical antipsychotic drugs. [123I]epidepride single photon emission tomography (SPET) study. Br J Psychiatry 1999;175:231-8.
95. Paquet F, Soucy JP, Stip E, Levesque M, Elie A, Bedard MA. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia. J Neuropsychiatry Clin Neurosci 2004;16:47-56. (Pubitemid 38233363)
96. Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 2003;28:1531-7.
97. Raedler TJ, Knable MB, Jones DW, Lafargue T, Urbina RA, Egan MF et al. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 2000;23:56-68.
98. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35. (Pubitemid 38625335)
99. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000;97:8104-9.
100. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000;31:371-84.
101. Abi-Dargham A, Kegeles LS, Martinez D, Innis RB, Laruelle M. Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohort. Eur Neuropsychopharmacol 2003;13:459-68.
102. Laruelle M, Huang Y. Vulnerability of positron emission tomography radiotracers to endogenous competition. New insights. Q J Nucl Med 2001;45:124-38.
103. Farde L, Wiesel FA, Halldin C, Sedvall G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988;45:71-6.
104. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002;7:317-21.